Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

Eurofins' empowerDX launches PFAS Exposuretm in the U.S, the First At-Home Blood Test to Detect and Measure 40+ PFAS Compounds

Today, Eurofins (Paris:ERF) subsidiary empowerDX has launched PFAS Exposuretm in the United States, the first direct to consumer at-home test to determine levels of PFAS in a person's blood and measure 47 of the PFAS "forever chemical" compounds.

Per- and Polyfluorinated Alkyl Substances (PFAS), such as PFOA and PFOS, known as "forever chemicals", characteristically resist natural breakdown in the environment and human bodies. The US Centers for Disease Control and Prevention (CDC) reports that exposure to these chemicals may cause adverse health effects, such as cancer, thyroid disease, immune suppression, elevated cholesterol, respiratory disease, and decreased fertility. One report by the CDC's National Health and Nutrition Examination Survey (NHANES) found PFAS in the blood of 97% of Americans.

The identification of PFAS through blood testing is a significant milestone. PFAS Exposuretm, developed by Eurofins Environment Testing companies and their research partners, and being launched in the U.S by empowerDX, is a self-administered sampling kit, which is the first of its kind and uses a simple finger prick. To date, testing for PFAS in blood has relied on serum as an estimation for whole blood and required a blood draw conducted by a healthcare practitioner. Eurofins' PFAS Exposuretm collection kits are an all-in-one solution that include the essentials for collection and transport, allowing participants to self-collect samples at home or work, and submit them directly to the laboratory.

The PFAS Exposure kit is available in the United States through Eurofins' at-home health testing business, empowerDX. Kits can be purchased online for $399 and are shipped directly to the customer's home or business.

To learn more, please visit this website.

About Eurofins ? the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

These press releases may also interest you

at 10:04
New parenthood. It's nothing you could have ever expected or predicted. Incredible highs and intense love, all intermixed with deep anxieties that can leave you feeling overwhelmed, lonely, and vulnerable. In fact, a new survey from Tommee Tippee...

at 10:00
The California Attorney General and Cedars-Sinai Health System have selected Berkeley Research Group (BRG) Managing Director Frank Stevens individually and BRG as the firm to serve as the court-appointed independent monitor overseeing compliance of...

at 10:00
Realty Trust Group (RTG) has proudly partnered with our health system clients for decades to provide property management services that help advance their real estate building investments. We are committed to serving with excellence the patients,...

at 10:00
Vela Diagnostics announced today the launch of its new PathoKey® MP UTI ID and AMR PCR Test for research use only (RUO*). This multiplex PCR-based test allows for the in vitro detection and differentiation of 14 pathogens that cause urinary tract...

at 10:00
The "Medical and Recreational Cannabis - A Global Overview" report has been added to ResearchAndMarkets.com's offering. CBD-Intel has compiled and classified the regulatory data on medical and recreational cannabis in over 57 jurisdictions around the...

at 10:00
Non-profit behavioral design firm ideas42 today announced the formation of a new specialized advisory council to significantly expand the potential impact of behavioral science in the global health sector....

News published on 21 january 2022 at 10:05 and distributed by: